Drug Trial News

RSS

Afinitor tablets decrease size of SEGA associated with tuberous sclerosis

The New England Journal of Medicine (NEJM) today published a study that found patients taking Afinitor (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS).

4 Nov 2010

Etanercept plus MTX improves height, weight, and BMI in children with juvenile idiopathic arthritis

Researchers from the Cincinnati Children's Hospital Medical Center observed a statistically significant increase in mean height, weight, and body mass index (BMI) percentiles in patients with juvenile idiopathic arthritis (JIA) who were treated with etanercept or etanercept plus methotrexate (MTX). JIA patients treated with MTX alone did not display an increase in growth percentiles.

4 Nov 2010

New antibody with SGN-35 drug produces remission in Hodgkin lymphoma

An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38 percent of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in a phase I clinical trial, investigators report in the Nov. 4 issue of the New England Journal of Medicine.

4 Nov 2010

Positive results from Lithera's LIPO-102 Phase IIb clinical study for abdominal fat reduction

Lithera, Inc. today announced positive results from a Phase IIb clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.

4 Nov 2010

Nymox awarded federal grant for NX-1207 Phase III BPH clinical trial program

Nymox Pharmaceutical Corporation announced today that it has been awarded a grant of $244,479.25 from the U.S Government under the Qualifying Therapeutic Discovery Project for its ongoing Phase III clinical trial program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH). The grant was the maximum allowable for an individual development program.

4 Nov 2010

Aeolus receives $489,000 grant under QTDP program for two lead compounds

Aeolus Pharmaceuticals, Inc. today announced that it has been awarded a total of approximately $489,000 under the Qualifying Therapeutic Discovery Grant Program (QDTP) administered by the Internal Revenue Service and the Department of Health and Human Services.

4 Nov 2010

Bristol-Myers Squibb and Simcere partner to co-develop oncology compound

Bristol-Myers Squibb Company and Simcere Pharmaceutical Group, a leading pharmaceutical company in China, today announced an innovative strategic partnership to co-develop BMS-817378, a preclinical small molecule MET/VEGFR-2 inhibitor.

4 Nov 2010

Biogen Idec and Cardiokine terminate lixivaptan collaboration

Biogen Idec and Cardiokine, Inc. today announced that they have agreed to dissolve their collaboration on lixivaptan. The termination of the collaboration, which began in 2007, triggers the return of all rights to lixivaptan to Cardiokine.

4 Nov 2010

PolyMedix receives $488,958 grants under QTDP program

PolyMedix, Inc. a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced today that it has been awarded two cash grants totaling $488,958 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

Bortezomib reduces inflammation and promotes bone healing in arthritis models

A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis (RA). In this study, bortezomib displayed favorable effects in an animal model of inflammatory arthritis that mimics RA, in reducing disease severity and inflammation, and promoting bone healing. Full findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

3 Nov 2010

QLT third quarter sales decreases 12.9% to $20.5 million

QLT Inc. today reported financial results for the third quarter ended September 30, 2010. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

3 Nov 2010

Incyte announces achievement of $50 million in INCB18424 clinical trial

Incyte Corporation announced today the achievement of $50 million in milestones as part of the Incyte-Novartis collaboration and license agreement for INCB18424.

3 Nov 2010

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

AstraZeneca announced today that results from TITAN, a 12-week study of SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol in African American patients with moderate to severe persistent asthma, showed significant improvement in lung function for patients taking SYMBICORT compared with those using budesonide alone.

3 Nov 2010

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Immune Network Ltd. a company in the business of discovery and development of immune-based therapies, today announced that patient enrollment will be completed next week for the company's future partner Immunitor's Phase 2b imm01 trial of V5 immunotherapy in 120 patients with tuberculosis.

3 Nov 2010

GenVec receives $244,479 grant under QTDP program

GenVec, Inc. announced today that it was awarded a cash grant of approximately $244,479 under the U.S. Government's Qualifying Therapeutic Discovery Project program.

3 Nov 2010

Celsion receives $244,000 grant under QTDP program

Celsion Corporation today announced that the company has been awarded a $244,000 grant under the Qualifying Therapeutic Discovery Project (QTDP) program under The Patient Protection and Affordable Care Act of 2010 (PPACA).

3 Nov 2010

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that three of the Company's therapeutic development programs, VIMOVO (naproxen / esomeprazole magnesium) (formerly PN400), PA32540 and PA65020, qualified to receive federal grant funding under The Patient Protection and Affordable Care Act.

3 Nov 2010

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, announced today that it has established a Scientific Advisory Board to help advance the company's research and clinical studies in type 1 diabetes.

3 Nov 2010

BioCryst receives $1.1 million in grants under QTDP program

BioCryst Pharmaceuticals, Inc. today announced that the Company had been awarded $1.1 million in grants under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program to advance the development of the Company's clinical programs for peramivir, BCX4208 and forodesine, as well as the pre-clinical BCX4161 kallikrein inhibitor and JAK inhibitor programs.

3 Nov 2010